Sensei Biotherapeutics (NASDAQ:FTH) Shares Down 5.3% – Should You Sell?

Sensei Biotherapeutics, Inc. (NASDAQ:FTH)’s share price fell 5.3% during trading on Friday . The company traded as low as $37.26 and last traded at $36.9150. Approximately 157,405 shares traded hands during mid-day trading, a decline of 27% from the average daily volume of 216,524 shares. The stock had previously closed at $39.00.

Wall Street Analyst Weigh In

FTH has been the topic of a number of recent analyst reports. Oppenheimer began coverage on shares of Sensei Biotherapeutics in a research note on Tuesday, July 28th. They set an “outperform” rating and a $60.00 price target on the stock. BTIG Research reissued a “buy” rating and set a $55.00 price objective on shares of Sensei Biotherapeutics in a report on Thursday, July 16th. Citigroup started coverage on shares of Sensei Biotherapeutics in a research report on Friday, May 22nd. They set a “buy” rating and a $55.00 target price on the stock. Wall Street Zen upgraded shares of Sensei Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 22nd. Finally, Weiss Ratings began coverage on Sensei Biotherapeutics in a research note on Wednesday, June 17th. They set a “sell (d-)” rating on the stock. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $55.00.

Sensei Biotherapeutics Price Performance

The firm has a market cap of $969 million, a price-to-earnings ratio of -0.26 and a beta of -0.28. The company has a 50-day moving average price of $31.05.

Sensei Biotherapeutics (NASDAQ:FTH) last posted its earnings results on Tuesday, August 4th. The company reported ($2.84) earnings per share for the quarter, beating the consensus estimate of ($5.04) by $2.20. On average, equities analysts predict that Sensei Biotherapeutics, Inc. will post -13.18 EPS for the current year.

Insider Activity at Sensei Biotherapeutics

In related news, CFO Brian C. Stephenson purchased 9,391 shares of the company’s stock in a transaction on Wednesday, June 24th. The stock was bought at an average price of $26.13 per share, with a total value of $245,386.83. Following the completion of the transaction, the chief financial officer owned 26,804 shares of the company’s stock, valued at approximately $700,388.52. This represents a 53.93% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Anand Kiran Parikh purchased 2,806 shares of the company’s stock in a transaction on Monday, June 22nd. The shares were bought at an average cost of $19.76 per share, with a total value of $55,446.56. Following the transaction, the chief executive officer directly owned 764,234 shares of the company’s stock, valued at $15,101,263.84. This represents a 0.37% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased a total of 49,494 shares of company stock valued at $1,188,822 over the last 90 days. Insiders own 7.00% of the company’s stock.

Institutional Trading of Sensei Biotherapeutics

A number of large investors have recently made changes to their positions in FTH. Bank of America Corp DE raised its stake in Sensei Biotherapeutics by 10,692.5% in the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after purchasing an additional 32,719 shares during the last quarter. Alyeska Investment Group L.P. acquired a new stake in shares of Sensei Biotherapeutics during the 2nd quarter worth about $3,610,000. Renaissance Technologies LLC grew its holdings in shares of Sensei Biotherapeutics by 178.2% during the first quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock worth $1,010,000 after buying an additional 20,525 shares in the last quarter. Stempoint Capital LP purchased a new stake in shares of Sensei Biotherapeutics during the first quarter worth about $4,188,000. Finally, Vivo Capital LLC acquired a new position in shares of Sensei Biotherapeutics in the first quarter valued at approximately $22,758,000. Institutional investors and hedge funds own 10.50% of the company’s stock.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.